AP2011005665A0 - Detection of HIV-related proteins in urine. - Google Patents

Detection of HIV-related proteins in urine.

Info

Publication number
AP2011005665A0
AP2011005665A0 AP2011005665A AP2011005665A AP2011005665A0 AP 2011005665 A0 AP2011005665 A0 AP 2011005665A0 AP 2011005665 A AP2011005665 A AP 2011005665A AP 2011005665 A AP2011005665 A AP 2011005665A AP 2011005665 A0 AP2011005665 A0 AP 2011005665A0
Authority
AP
ARIPO
Prior art keywords
hiv
urine
detection
related proteins
proteins
Prior art date
Application number
AP2011005665A
Other languages
English (en)
Inventor
Chamberlain Obialo
Khalid Bashir
Claudeette Mitchell-Ali
Original Assignee
Morehouse School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morehouse School Of Medicine filed Critical Morehouse School Of Medicine
Publication of AP2011005665A0 publication Critical patent/AP2011005665A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AP2011005665A 2008-10-06 2009-10-05 Detection of HIV-related proteins in urine. AP2011005665A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10294108P 2008-10-06 2008-10-06
US12/572,652 US10545149B2 (en) 2008-10-06 2009-10-02 Detection of HIV-related proteins in urine
PCT/US2009/059500 WO2010042425A2 (en) 2008-10-06 2009-10-05 Detection of hiv-related proteins in urine

Publications (1)

Publication Number Publication Date
AP2011005665A0 true AP2011005665A0 (en) 2011-04-30

Family

ID=42076105

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005665A AP2011005665A0 (en) 2008-10-06 2009-10-05 Detection of HIV-related proteins in urine.

Country Status (7)

Country Link
US (3) US10545149B2 (de)
EP (1) EP2331969B1 (de)
CN (2) CN106383227B (de)
AP (1) AP2011005665A0 (de)
AU (2) AU2009302612B2 (de)
CA (1) CA2738666C (de)
WO (1) WO2010042425A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) * 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2542696B1 (de) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Theranostik-biomarker
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
CA2806211A1 (en) * 2010-07-22 2012-01-26 Georgetown University Mass spectrometric methods for quantifying npy 1-36 and npy 3-36
CN102323281B (zh) * 2011-08-22 2013-09-18 爱威科技股份有限公司 液体性质检测方法和系统
US9579273B2 (en) 2011-12-14 2017-02-28 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
WO2014108480A1 (en) * 2013-01-09 2014-07-17 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
EP3004397A1 (de) * 2013-05-28 2016-04-13 INSERM - Institut National de la Santé et de la Recherche Médicale Verwendung von hiv-harnnukleinsäuren zur diagnose und überwachung hiv-assoziierter nephropathie (hivan)
CN103468642A (zh) * 2013-09-23 2013-12-25 山西大学 一种分离细胞培养基中外泌体的方法
US9927427B2 (en) 2013-10-24 2018-03-27 Agency For Science, Technology And Research Exosome recovery methods with low molecular weight organic zwitterions
FR3014198B1 (fr) * 2013-12-03 2017-03-03 Biomerieux Sa Procede d'isolement d'exosomes
WO2015112382A1 (en) 2014-01-21 2015-07-30 Morehouse School Of Medicine Exosome-mediated detection of infections and diseases
CN103900890A (zh) * 2014-03-07 2014-07-02 南方医科大学第三附属医院 一种采用纳米膜浓缩法提取尿微囊泡的方法
CN105505854B (zh) * 2016-01-14 2019-07-12 上海市第六人民医院 来源于人尿液细胞的外泌体的获取方法与应用
CN107153023A (zh) * 2016-03-02 2017-09-12 上海润腾生物科技有限公司 一种分离尿液中外泌体的方法
WO2018070479A1 (ja) * 2016-10-13 2018-04-19 合同会社みらか中央研究所 細胞外小胞の回収方法
CN108333263A (zh) * 2017-01-20 2018-07-27 北京蛋白质组研究中心 一种尿蛋白制备方法及尿蛋白质组的检测方法
CN106929467B (zh) * 2017-02-16 2021-05-18 上海交通大学 一种分离高纯度尿液外泌体的方法和试剂盒
JP7045527B2 (ja) * 2018-09-20 2022-03-31 ティーエイエムアイアールエヌエイ・ゲーエムベーハー 肝機能障害の予測のためのマイクロｒｎａシグネチャ
CN114397388B (zh) * 2022-01-11 2024-03-19 杭州昱鼎生物科技有限公司 一种基于peg沉淀法与sec柱法相结合的尿液外泌体提取试剂盒及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830641A (en) * 1986-01-22 1998-11-03 Institut Pasteur In vitro diagnostic assays for the detection of HIV-1 or HIV-2 employing viral-specific antigens and antibodies
US5580739A (en) * 1986-01-22 1996-12-03 Institut Pasteur Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2
US5364933A (en) * 1986-03-03 1994-11-15 Institut Pasteur Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
US5208321A (en) * 1988-06-09 1993-05-04 Institut Pasteur HIV-2 transmembrane glycoprotein homodimer (GP 80)
ATE423856T1 (de) * 1989-06-02 2009-03-15 Pasteur Institut Nukleotid-sequenzen von hiv-1, hiv-2 und siv retrovirusgenomen, ihre verwendung zur amplifizierung von pol-sequenzen dieser retroviren und zur in vitro diagnostik von diesen viren verursachten infektionen
AU639457B2 (en) * 1989-06-02 1993-07-29 Abbott Laboratories Hiv p24 quantitation panel
US5256561A (en) * 1991-12-20 1993-10-26 Abbott Laboratories Monoclonal antibody to HIV-2 and uses thereof
US5462852A (en) * 1992-10-28 1995-10-31 The Government Of The United States Of America, As Represented By The Secretary, Dhhs HIV Nucleocapsid protein capture assay and method of use
AU9498098A (en) * 1997-09-22 1999-04-12 Chiron Corporation Buffers for stabilizing antigens
US20060252075A1 (en) * 1998-08-21 2006-11-09 Neovacs Method for monitoring anti-HIV treatment in HIV infected individuals
US20040106136A1 (en) * 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
US6383740B2 (en) * 1999-07-30 2002-05-07 Bioergonomics, Inc. Methods for simultaneously detecting both members of a binding pair
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
EP1411770A4 (de) * 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
CA2532084A1 (en) * 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences
WO2005044292A2 (en) * 2003-11-05 2005-05-19 Institut De Recherche Pour Le Developpement (Ird) Biomarkers of resistance to hiv-infections in humans and biological applications thereof
JP2008501336A (ja) * 2004-06-02 2008-01-24 ソースフアーム・インコーポレイテツド Ｒｎａを含有する微小胞およびそのための方法
DK3517151T3 (da) 2006-03-09 2021-07-12 Aethlon Medical Inc Ekstrakorporal fjernelse af mikrovesikulære partikler
US8357296B2 (en) * 2007-09-24 2013-01-22 Emd Millipore Corporation Centrifugal filter
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes

Also Published As

Publication number Publication date
US10545149B2 (en) 2020-01-28
EP2331969B1 (de) 2014-11-26
US20120214151A1 (en) 2012-08-23
CA2738666C (en) 2018-05-15
CN102171574B (zh) 2016-09-21
AU2016244203A1 (en) 2016-11-03
CN102171574A (zh) 2011-08-31
US20120208175A1 (en) 2012-08-16
US9541554B2 (en) 2017-01-10
AU2016244203B2 (en) 2018-06-21
CN106383227A (zh) 2017-02-08
US20100086956A1 (en) 2010-04-08
EP2331969A4 (de) 2012-05-16
WO2010042425A3 (en) 2010-07-22
CA2738666A1 (en) 2010-04-15
AU2009302612A1 (en) 2010-04-15
CN106383227B (zh) 2019-02-01
EP2331969A2 (de) 2011-06-15
US9581596B2 (en) 2017-02-28
AU2009302612B2 (en) 2016-07-14
WO2010042425A2 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
AP2011005665A0 (en) Detection of HIV-related proteins in urine.
IL250624B (en) Anti-fgfr3 antibodies and methods of using them
BRPI0917335A2 (pt) sistema de bebida de mistura posterior
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
AP2929A (en) Anti-TRKA antibodies and derivatives thereof
PL2182105T3 (pl) Czujnik mętności
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
ZA201100261B (en) Anti-hepcidin-25 selective antibodies and uses thereof
ZA201004899B (en) Biological materials and uses thereof
FI20065182A0 (fi) Fermentoitu elintarvike
GB0807018D0 (en) Antibodies and treatment
DE602007011305D1 (de) Kaffee- und teedosiersystem
GB0915869D0 (en) Composition and assay method for the detection of patogenic bacteria
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
IL194940A0 (en) Protein assay
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
GB0816976D0 (en) Protein
IL219136A0 (en) Anti-hepsin antibodies and methods using same
ZA201200287B (en) Detection of occult blood in feces or urine
GB0812277D0 (en) Antibody and uses thereof
GB0811362D0 (en) Biological materials and uses thereof
GB0818627D0 (en) Protein
GB0802980D0 (en) Biological materials and uses thereof
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina